Dr. Carlo-Stella on Updated Results on RG6234 Activity in R/R Multiple Myeloma

Carmelo Carlo-Stella, MD, PhD, discusses updated results from a phase 1 dose-escalation study of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Carmelo Carlo-Stella, MD, PhD, Department of Biomedical Sciences, Humanitas University, Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, discusses updated results from a phase 1 dose-escalation study (NCT04557150) of subcutaneous (SC) and intravenous (IV) RG6234 in relapsed/refractory multiple myeloma.

The study evaluated the safety and pharmacokinetics of RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, in patients with relapsed or refractory multiple myeloma who have no sufficient available or tolerable standard-of-care treatments.

Data presented at the 2022 ASH Annual Meeting demonstrated that RG6234 was highly effective when administered either intravenously or subcutaneously, Carlo-Stella states. The overall response rate (ORR) was 71.4% in the IV cohort and 63.6% in the SC cohort. Notably, over 50% of patients in the IV cohort displayed a very good partial response or better.

Additionally, 71.4% of patients who achieved complete remission (CR) became minimal residual disease (MRD) negative, Carlo-Stella continues. These data support the efficacy of RG6234 and indicate the potential for achieving long-term, durable responses with this agent.

Related Videos
View All
Related Content